A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Clinical trial NCT06863272 · RECRUITING
Trial details
- NCT number
- NCT06863272
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-03
- Primary completion
- 2031-04-01
- Enrollment
- 360
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.